← All IPOs

Sahajanand Medical Technologies Ltd IPO

SMT · Main board · HealthcareListed
Read filingAllotmentStock listed on 23 October
Price band
₹327 to ₹344
Issue size
₹475 Cr
Issue price
₹344
Lot size
43 shares
Listing return
+7.89%

Listed ₹371.15

  1. Opens

    15 Oct 2026

  2. Closes

    19 Oct 2026

  3. Allotment

    21 Oct 2026

  4. Listing

    23 Oct 2026

Subscription

About the company

Sahajanand Medical Technologies Limited makes and sells devices for vascular and structural heart procedures. Started in 2001, its range covers vascular products such as coronary stents and balloon catheters, structural heart items like TAVI devices and occluders, plus renal stents, peripheral drug-coated balloons, and traded medical goods.

Sales happen through direct, hybrid, and distributor channels. In FY26 the company earned revenue from 77 countries, India included, with operations in Europe and other overseas markets. It runs three plants (two in India, one in Thailand) and two R&D centres (India and Thailand) that work on device development and product upgrades.

Use of proceeds

This is an offer-for-sale (OFS), so the company itself gets no money from the issue. Net proceeds go to the promoter selling shareholders in proportion to the shares each offers. The main aim is to list the equity shares on the stock exchanges, which should raise visibility and brand recognition, give existing shareholders liquidity, and create a public market for the shares in India.

Founded1999MDMr Bhargav Dhirajlal Kotadia

Key performance indicators (KPIs)

for the three month period ended June 30, 2026

  • ROE2.07%
  • ROCE3.16%
  • EBITDA Margin13.81%
  • PAT Margin4.29%
  • Return on Net Worth (RoNW)2.31%

Debt/Equity Ratio

0.33

EPS (Pre IPO)

6.8

Net Asset Value (NAV) per Equity Share

64.3

View table
KPIValue (for the three month period ended June 30, 2026)
ROE (%)2.07
ROCE (%)3.16
EBITDA Margin (%)13.81
Debt/Equity Ratio0.33
PAT Margin (%)4.29
EPS (Pre IPO) (₹)6.8
Return on Net Worth (RoNW) (%)2.31
Net Asset Value (NAV) per Equity Share (₹)64.3

Financials

₹ crore

Revenue

1,210.5

+18.1%

Total Assets

1,276.43

+16.6%

Profit

69.08

+174.7%
View table
Line202420252026
Revenue901.61,024.881,210.5
Total Assets970.581,094.91,276.43
Profit-7.3525.1569.08

Book running lead managers & registrar

Book running lead managersMotilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities, Capital Markets (India) Private Limited, Nuvama Wealth Management Limited
Registrar to the issueMUFG Intime India Private Limited

Sahajanand Medical Technologies IPO contact details

Company nameSahajanand Medical Technologies Limited
Registered officeSahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat – 395 004, India
Phone022 49564000
Emailinvestors.grievance@smt.in
Websitewww.smtpl.com

Sahajanand Medical Technologies IPO registrar contact details

Company nameMUFG Intime India Private Limited
Phone+91 810 811 4949
Emailsahajanandmedical.ipo@in.mpms.mufg.com
Websitein.mpms.mufg.com/

Thesis

  • 1

    As per the F&S Report, the company accounted for almost 25% of India's drug-eluting stent (DES) market by sales volume in FY26, and ranked among the top five by DES volume in Germany, Spain, Poland, and Brazil as of March 31, 2026.

  • 2

    Products reached 77 countries in FY26, and overseas revenue climbed from Rs 587.84 crore in FY24 to Rs 704.23 crore in FY25 and Rs 894.20 crore in FY26, a CAGR of 23.34%.

  • 3

    Two R&D centres, in Surat and Nonthaburi, back the business; as of the RHP date the company held 119 granted patents worldwide, 78 pending applications, and five design registrations in India, with R&D spending at 9.04%, 9.07%, and 8.61% of revenue in FY24, FY25, and FY26.

  • 4

    Clinical backing is broad: as of June 30, 2026, 75 studies supported its products (66 finished, nine ongoing), and research has appeared in journals including The Lancet and The New England Journal of Medicine.

  • 5

    Three plants in Surat, Hyderabad, and Thailand all carry ISO 13485:2016 quality certification, along with approvals such as CDSCO, CE, ANVISA, TGA Australia, and Korean GMP depending on the site.

  • 6

    Manufacturing is integrated in-house, covering balloon catheters, laser cutting, electropolishing, drug and polymer coating, and valve production; about 33% of available space at the Hyderabad plant is in use, leaving room to expand.

  • 7

    Acquisitions of Vascular Concepts and Vascular Innovations opened the structural heart segment, while Imex in Spain and Zarek in Brazil strengthened distribution, with revenue from Imex and Zarek growing at CAGRs of 52.10% and 23.91% since acquisition in FY20.

Application details

  • Regular

    ₹327 - ₹344 · Upto ₹2 Lakhs

    43shares
  • Employee

    ₹327 - ₹344 · Upto ₹5 Lakhs

    43shares
  • High Networth Individual

    ₹327 - ₹344 · ₹2 - ₹5 Lakhs

    43sharesMin 602

Figures come from the company filing. This is not a recommendation.